NewGenIvf Group Stock Set to Reverse Split on Tuesday, September 1st (NASDAQ:NIVF)

NewGenIvf Group Limited (NASDAQ:NIVF) shares are going to reverse split on Tuesday, September 1st. The 1-3 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, August 31st.

NewGenIvf Group Price Performance

Shares of NASDAQ:NIVF opened at $0.58 on Monday. NewGenIvf Group has a 1-year low of $0.45 and a 1-year high of $513.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.98 and a current ratio of 3.12. The business has a fifty day moving average price of $1.22 and a 200-day moving average price of $4.34.

Analyst Ratings Changes

Several brokerages recently commented on NIVF. Weiss Ratings reissued a “sell (d)” rating on shares of NewGenIvf Group in a research report on Friday, July 24th. Wall Street Zen raised shares of NewGenIvf Group to a “hold” rating in a report on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, NewGenIvf Group currently has an average rating of “Sell”.

Insider Buying and Selling

In other NewGenIvf Group news, major shareholder Financial Lp Hrt sold 28,439 shares of NewGenIvf Group stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $2.40, for a total value of $68,253.60. Following the completion of the sale, the insider owned 18,187 shares of the company’s stock, valued at approximately $43,648.80. This trade represents a 60.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 31.80% of the company’s stock.

NewGenIvf Group Company Profile

NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.

NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.